Back to top
more

Incyte (INCY)

(Delayed Data from NSDQ)

$53.76 USD

53.76
1,407,351

+0.67 (1.26%)

Updated May 3, 2024 04:00 PM ET

After-Market: $53.77 +0.01 (0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value D Growth D Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 27% (69 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Earnings Preview: Incyte (INCY) Q3 Earnings Expected to Decline

by Zacks Equity Research

Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Nalak Das headshot

A Bear Market Rally or Markets Forming a Solid Base: 5 Picks

by Nalak Das

We have narrowed our search to five large-cap U.S. companies with strong potential for the rest of 2022. These are: IBKR, INCY, WMB, HUBB and LW.

Is Incyte (INCY) a Solid Growth Stock? 3 Reasons to Think "Yes"

by Zacks Equity Research

Incyte (INCY) is well positioned to outperform the market, as it exhibits above-average growth in financials.

INCY vs. GMAB: Which Stock Is the Better Value Option?

by Zacks Equity Research

INCY vs. GMAB: Which Stock Is the Better Value Option?

Here's Why You Should Add Intra-Cellular Therapeutics (ITCI) Stock Now

by Zacks Equity Research

Intra-Cellular's (ITCI) product revenues are primarily driven by higher sales of its schizophrenia and bipolar disorder drug Caplyta. Caplyta is also being evaluated for other CNS indications.

Is Invesco S&P 500 Equal Weight Health Care ETF (RYH) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for RYH

Pfizer (PFE) Alopecia Drug Filings Get Accepted by FDA, EMA

by Zacks Equity Research

FDA accepts Pfizer's (PFE) NDA for ritlecitinib for treating severe alopecia areata. The EMA also accepts the MAA for a similar patient population.

Should You Invest in the Invesco S&P 500 Equal Weight Health Care ETF (RYH)?

by Zacks Equity Research

Sector ETF report for RYH

Incyte (INCY) Down 2.9% Since Last Earnings Report: Can It Rebound?

by Zacks Equity Research

Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Biotech Stock Roundup: BMY's Study Update, INCY's Drug Label Expansion, MRNA News

by Zacks Equity Research

Regulatory updates from Bristol Myers (BMY) and Incyte (INCY) are a few key highlights from the biotech sector during the past week.

Incyte (INCY) Gets FDA Nod for Label Expansion of Pemazyre

by Zacks Equity Research

Incyte (INCY) obtains FDA approval for Pemazyre for a second indication - the treatment of adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.

Novartis (NVS) NSCLC Study Fails to Meet Primary Endpoint

by Zacks Equity Research

Novartis (NVS) suffers a setback as canakinumab fails to meet the primary goal in yet another study for lung cancer.

Incyte's (INCY) Earnings and Revenues Surpass Estimates in Q2

by Zacks Equity Research

Incyte's (INCY) earnings and revenues trump estimates in the second quarter of 2022. The company raises the bottom end of full-year Jakafi's net product revenue guidance.

Incyte (INCY) Q2 Earnings and Revenues Surpass Estimates

by Zacks Equity Research

Incyte (INCY) delivered earnings and revenue surprises of 27.85% and 11.04%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Drug, Biotech Stocks' Q2 Earnings on Aug 2: GILD, INCY & More

by Zacks Equity Research

Let's check out how the four pharma/drug/biotech companies are placed before the quarterly earnings release on Aug 2.

Myovant Sciences (MYOV) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Myovant Sciences (MYOV) delivered earnings and revenue surprises of -69.23% and 8.57%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Incyte (INCY) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Incyte's (INCY) top line is likely to have been driven by sales of its lead drug, Jakafi, in the second quarter.

Biotech Stock Roundup: APLS, NVAX Gain on Updates, INCYs Regulatory News & More

by Zacks Equity Research

'Regulatory and other updates from Apellis (APLS) and Novavax (NAVX) are a few key highlights from the biotech sector during the past week.

INCY vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

INCY vs. TECH: Which Stock Is the Better Value Option?

Incyte (INCY) Gets FDA Nod for Label Expansion of Opzelura

by Zacks Equity Research

Incyte (INCY) Opzelura cream 1.5% gets FDA approval for another indication - nonsegmental vitiligo in adult and pediatric patients 12 years of age and older.

Incyte (INCY) Outperforms Industry YTD: What Lies Ahead?

by Zacks Equity Research

Incyte (INCY) outperforms the industry in the year so far as lead drug Jakafi maintains momentum. Pipeline progress has also been encouraging.

Novartis' (NVS) Oncology Drugs Get Approval for Label Expansion

by Zacks Equity Research

Novartis (NVS) obtains regulatory approval for label expansion of Tafinlar + Mekinist and Tabrecta.

MorphoSys (MOR) Gains on Oncology Collaboration With Pfizer

by Zacks Equity Research

MorphoSys (MOR) and Pfizer collaborate to develop a combination of MOR's Monjuvi and Pfizer's checkpoint inhibitor candidate, TTI-622, for treating r/r DLBCL.

Lilly (LLY), Incyte's Olumiant Gets FDA Nod for Alopecia Areata

by Zacks Equity Research

Lilly (LLY) and Incyte's Olumiant is the first-ever FDA-approved systemic treatment for alopecia areata patients.

Lilly (LLY) Eczema Candidate Keeps Skin Clearance for One Year

by Zacks Equity Research

Data from late-stage studies conducted by Eli Lilly (LLY) shows that its atopic dermatitis drug maintained improvement in skin clearance and itch relief in 8 of 10 patients for a one-year treatment.